GENOR BIOPHARMA DL-00002 (67N0) - Total Liabilities
Based on the latest financial reports, GENOR BIOPHARMA DL-00002 (67N0) has total liabilities worth €226.09 Million EUR (≈ $264.32 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore GENOR BIOPHARMA DL-00002 annual equity growth to track the company's year-over-year net asset growth rate.
GENOR BIOPHARMA DL-00002 - Total Liabilities Trend (2021–2024)
This chart illustrates how GENOR BIOPHARMA DL-00002's total liabilities have evolved over time, based on quarterly financial data.
GENOR BIOPHARMA DL-00002 Competitors by Total Liabilities
The table below lists competitors of GENOR BIOPHARMA DL-00002 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
China National Accord Medicines Corp Ltd
SHE:200028
|
China | HK$27.21 Billion |
|
SM Culture & Contents Co. Ltd
KQ:048550
|
Korea | ₩134.83 Billion |
|
Laxmi Goldorna House Ltd
NSE:LGHL
|
India | Rs1.19 Billion |
|
SBI Investment KOREA Co. Ltd
KQ:019550
|
Korea | ₩4.14 Billion |
|
Answear.com S.A.
WAR:ANR
|
Poland | zł641.88 Million |
|
Taseco Air Services JSC
VN:AST
|
Vietnam | ₫298.09 Billion |
|
Wielton S.A.
WAR:WLT
|
Poland | zł1.59 Billion |
|
Intertek Group PLC
LSE:ITRK
|
UK | GBX2.63 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down GENOR BIOPHARMA DL-00002's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is GENOR BIOPHARMA DL-00002 worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GENOR BIOPHARMA DL-00002's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GENOR BIOPHARMA DL-00002 (2021–2024)
The table below shows the annual total liabilities of GENOR BIOPHARMA DL-00002 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €138.05 Million ≈ $161.39 Million |
-46.11% |
| 2023-12-31 | €256.18 Million ≈ $299.50 Million |
-17.33% |
| 2022-12-31 | €309.87 Million ≈ $362.27 Million |
-16.19% |
| 2021-12-31 | €369.73 Million ≈ $432.25 Million |
-- |
About GENOR BIOPHARMA DL-00002
Edding Genor Group Holdings Limited, together with its subsidiaries, engages in the research, development, manufacturing, and distribution of biopharmaceutical products in China, the United States, and internationally. The company offers GB491, a differentiated CDK4/6 inhibitor for advanced or metastatic breast cancer; GB261, a novel CD3/CD20 bispecific antibody which is in clinical development f… Read more